The European Agency for the Evaluation of Medicinal Products (EMEA) has appointed Pat O'Mahony, chief executive of the Irish Medicines Board (IMB), to its management board.
Mr O'Mahony will be Ireland's representative on the board, whose main responsibility is the evaluation and supervision of human and veterinary medicines to protect and enhance public and animal health in the EU. Mr O'Mahony, MVB, MVM, MBA, MRCVS, is a qualified veterinary surgeon and holds a Master's Degree in veterinary medicine and an MBA degree from the Michael Smurfit Graduate School of Business, UCD.
The EMEA board comprises one representative per member-state, two representatives of the European Parliament, European Commission and patient groups, and one representative from medical and veterinary groups.
EMEA is a decentralised body of the EU, based in London, which brings together the scientific resources of over 3,000 European experts from all member-states to ensure the highest level of evaluation and supervision of human and veterinary medicines. The agency also co-operates with international partners on regulatory issues. The appointment is for three years.